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Abstract: The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer
associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated
for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled
in humans more than thirty years ago. Since then, several other monoclonal antibodies have been
raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has
been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not
shown as much promise as initially heralded. In this review, we look at the reasons why and consider
alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial
cancer biomarker into a viable target for future personalized therapy.
Keywords: antibody; aptamer; cancer; EpCAM; immunotherapy; therapeutics
1. Introduction
Cancer therapy has progressed significantly in the last forty years. We have moved on, to an extent,
from the delivery of non-specific drugs, such as taxanes, vinca alkaloids, anthracyclines, and others [1].
While these drugs all showed promise, they are often delivered at suboptimal levels due to their
toxic side effects. However, a significant discovery in the 1970s by Kohler and Milstein led to the
development of monoclonal antibodies [2]. Following this, functional screens were performed whereby
cancer cells were injected into mice to generate monoclonal antibodies and a novel cancer specific
cell surface antigen was discovered [3]. The epithelial cell adhesion molecule (EpCAM), or CD326,
was one of the first cancer biomarkers that were discovered in the 1970s. This cell surface, type 1
transmembrane glycoprotein, is highly expressed in epithelial cancers, making it an ideal target for
both diagnosis and therapy [4–6]. What makes EpCAM a very interesting molecule for targeted
therapeutics though, is that it is localised to the basolateral membrane in normal epithelial tissue,
but during the progression from normal cell to cancer cell, the expression pattern changes to an intense
uniform membranous over-expression [4]. It is this intercellular sequestration that is thought to prevent
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therapeutic modalities targeting EpCAM from harming normal epithelial tissue as the intercellular
boundaries are very dense and highly organised structures [7].
2. EpCAM as a Functional Molecule
EpCAM, as its name suggests, is involved in cell adhesion through Ca2+-independent homophilic
cell-cell adhesion in cells that normally lack cell-cell interactions. However, EpCAM is not associated
with any classical junctional structure or with any of the four major families of cell adhesion molecules
(CAMs) [3]. In fact, while the other CAMs form tight connections between cells, EpCAM is relatively
weak, and EpCAM expressing cells are only loosely interconnected. EpCAM has also been shown to
modulate other CAM functions, and weakens E-Cadherin-mediated intercellular adhesion through
reduced stability [3]. As well, contact inhibition and polarisation, which are typical epithelial features,
are less strong in EpCAM-expressing cells. Finally, cell migration and motility are attenuated in murine
knock-out cells, suggesting that EpCAM plays a role in cancer cell invasion and metastasis, and that,
in cancer cells, where EpCAM is over-expressed, it acts as a negative regulator of adhesion [3,4,8]. It has
also more recently been suggested to be an oncogene, and in most types of cancers, it is associated
with poor prognosis [9,10]. Surprisingly though, increased EpCAM expression does not always
suggest poor prognosis for patients, and it is very much context-driven due to the distinct biology
that some subtypes of cancer have. For example, if EpCAM expression is considered for breast cancer,
an over-expression suggests poorer prognosis, greater tumour size, lymph node involvement, tumour
stage, and tumour grade [11,12]. However, if these cases are delineated into the distinct subtypes,
EpCAM expression is associated with an unfavourable prognosis in the basal like triple negative
breast cancers and luminal B subtypes, whereas in the human epidermal growth factor receptor 2
(HER2+) subtype, it is associated with a favourable prognosis [11]. Since the initial discovery of cancer
associated biomarkers in the 1970s, several other biomarkers have been discovered and have been
successfully targeted with therapeutics. So, why has EpCAM, which is expressed on the vast majority
of cancers of epithelial origin, failed to deliver on the initial promises of forty years ago?
3. Targeted Therapeutics—The First Wave
EpCAM was first identified as a cancer-specific cell surface antigen during a functional screen
in which cancer cells were injected into mice to generate antibodies [3,13]. The resultant hybridoma
cells were reliable sources of monoclonal antibodies and given that they could bind to markers on
cancer cells, these were considered as potential agents for targeted therapeutics. The first monoclonal
antibody to be tested in clinical trials was the EpCAM-specific murine IgG2a antibody 17-1A produced
in the ascites of mice and called edrecolomab. This antibody was first described in 1979, and tested
in humans in the first trial several years later in patients with gastrointestinal adenocarcinoma [14].
Initial reports suggested that edrecolomab induced anti-tumour activity through the activation of
an array of endogenous cytotoxic mechanisms, including both antibody-dependent cell-mediated
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), as well as potentially inducing
a host-idiotype antibody response [15,16]. However, while it showed some efficacy in earlier trials in
resected colorectal cancer, its benefits could not be replicated in larger clinical trials [17,18]. It also led
to significant adverse effects with both murine and chimeric clones of the antibody [13]. Given that
EpCAM appeared to be a perfect target, however, further work was conducted to generate antibodies
with moderate or high affinity to EpCAM, with the thinking that edrecolomab was inefficacious as
it only had a low affinity for its target. With a low affinity, edrecolomab bound only to cells with
high expression, but due to the heterogeneity of tumours, not all of the tumour cells overexpressed
EpCAM to the extent that the antibody theoretically bound to them. The next two antibodies that
were generated, 3622W94 and ING-1, were discontinued in clinical trials due to poor tolerability [13].
The issue with these were that, rather than sparing normal epithelial cells that have both a low target
expression and an almost hidden expression due to EpCAM only being present on the basolateral
membrane, they bound to all cells expressing EpCAM and caused acute pancreatitis. Having learnt
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from these experiences, the next antibody generated, Adecatumumab, had a moderate affinity for
EpCAM, and spared the normal cells while targeting the tumour cells. This antibody has shown efficacy
in clinical trials, and in one study of metastatic breast cancer, it reduced the number of metastases and
lowered tumour progression. However, when patients were stratified based on EpCAM expression,
it was patients who had a high expression of EpCAM that responded more favourably than those with
a low expression of EpCAM on their cell surface [19]. However, what may be of more importance to
the positive effects observed with Adecatumumab is that this antibody has been shown to have a small
but significant inhibitory effect on cell metabolism, suggesting that ADCC and CDC only play small
roles in the therapeutic effects of monoclonal antibodies [13].
4. How Do Monoclonal Antibodies Work as Therapeutics?
To understand why some of these therapeutic strategies did not work as expected,
an understanding of ADCC and/or CDC is required. Antibodies mainly function as therapeutics in
one of two ways, involving either effector cells of the immune system (ADCC) or independent of the
immune cells, requiring circulating proteins of the complement system (CDC) [20]. CDC occurs via
interactions with the Fc domain of the antibody. The Fc portion of the antibody binds via their Fab
domain to the surface of a cell, but can also bind to C1q and cause the deposition of complement,
which thus activates a cascade resulting in CDC [20,21]. For ADCC, at least as suggested through
in vitro studies, an effector to target cell ratio of 25–50:1 is required [22]. ADCC is the result of
Fc-gamma receptor (FcγR, CD16) mediated interaction with effector immune cells, such as natural
killer (NK) cells, macrophages, and granulocytes. The binding of FcγR to the Fc domain induces
the release of both granzyme and perforin from effector cells, which leads to target cell lysis and
Fc-dependent tumour cell phagocytosis [23]. These effects are dependent on a number of factors,
including the density of the antigen on the cell surface and the isotype of the antibody [21]. Indeed,
the effects of ADCC or CDC can specifically depend on the affinity of the antibody to either FcγR or
complement components, regardless of the affinity of the antibody to its target.
In a perfect scenario, the monoclonal antibodies would be infused and they would travel directly
to the tumour, where they bind to all the tumour cells, bind straight to either complement or CD16
positive cells, and cause cellular cytotoxicity. However, no targeted therapy immediately homes to
the tumour, but needs to come into contact with the biomarker on the tumour cells during normal
circulation and it can take up to 24 h for complete accumulation of antibodies in the tumour [24,25].
The vasculature of the tumour aids in ‘sucking in’ the targeting agent due to the leaky blood vessels.
However, due to a lack of lymphatic drainage, backpressure can prevent some macromolecules from
diffusing into the tumour, thus limiting the effective dose [26]. Antibodies with low affinity will
bind to the first target they find, but may be released, allowing for them to penetrate further into the
tumour than those with moderate to higher affinity, which would remain bound to the first cell surface
marker they encounter [26]. Additionally, some studies have shown that metastatic lesions have higher
expression levels of EpCAM than the primary tumours, suggesting that these antibodies might target
these secondary lesions rather than showing any benefit to the primary tumour [12,27].
For these antibodies to work, there needs to be an adequate number of antibodies that are attached
to the cells, and complement or CD16-positive cells in the vicinity of the tumour cells [24]. Given that
in vitro assays for ADCC take 4–16 h incubation, it is likely that the shortest amount of time for this
reaction to occur in vivo is several hours [21,23]. There is also the danger that due to limited penetration
of drugs due to both the backpressure and the size of the antibody, there is limited penetration of the
drugs through the tumour tissue [26,28,29]. This is more so the case when the antibody has a high
affinity for its target and binds to the first receptor it encounters. However, studies have shown that
ADCC effects do not necessarily correlate with antibody target expression, with one recent study
assessing the ADCC effects of Trastuzumab and demonstrating that ADCC activity did not correlate
with HER2 expression levels, with the cell line having a moderate expression of HER2 that had the
highest ADCC activity [23].
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Therefore, taking into account the other barriers in the way for the antibody to find the tumour,
overcome the barriers of backpressure, and binding to and staying bound to the one tumour cell for
long enough [20], an almost ‘perfect storm’ needs to occur for efficient tumour cell death. These factors
could explain why, in xenograft models, less than 20% of the administered dose of antibodies typically
interacts with the tumour [30]. However, this is not the only consideration for successful therapy.
Previous studies with Cetuximab have demonstrated that tumor cell killing only occurs if the antibody
remains bound to the outside of the cancer cell and is not internalised [31]). This is intuitive as the only
way for effector cells or complement to bind to the antibody and come into contact with the tumour cell
is if the antibody remains in contact with the cell within the microenvironment. However, studies have
shown that EpCAM is rapidly internalised following ligands binding to the cell surface receptor [32,33].
So, the question is, of the antibodies that have been developed for therapeutic targeting of EpCAM,
do they become internalised with the receptor, or remain within the vicinity of the cell when the
receptor becomes internalised? Also, if they remain in the vicinity of the cell, how much does this
hinder the ADCC or CDC process if they are continuously being released from the cell membrane?
Thus, as summarized in Figure 1, therefore, monoclonal antibodies need to combat a number of
environmental factors before they can get close to the tumour cells. Once in their vicinity, they face
a second set of challenges, such as maintaining contact with the cell, without being internalised,
for a sufficient period of time to engage effector cells or complement. Additionally, there needs to
be enough antibodies surrounding the cell to cause ADCC or CDC [24]. However, if the therapy
is dependent on tumour infiltrating immune cells that participate in ADCC, there also needs to be
a sufficient number of immune cells within the tumour microenvironment that can kill the tumour
cells [24]. Further, this is assuming that there are no immune suppressor cells, such as regulatory T cell
and myeloid-derived suppressor cells, which inhibit both NK cell function and ADCC activity [23,34].
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Figure 1. Mechanism of action of epithelial cell adhesion molecule (EpCAM) antibodies. (A) antibodies
pass through the leaky blood vessel walls but are moved back into circulation due to back pressure;
(B) while the EpCAM antibodies can bind to tumour cells, they can also bind to other cells
non-specifically; (C) low affinity antibodies may not remain bound to their target while high affinity
antibodies may be internalised with the receptor; (D) If the antibody is internalised, cytotoxic T cells
are not activated. RBC: red blood cell; EpEx: extracellular domain of EpCAM; EplCD: intracellular
domain of EpCAM; MHC: major histocompatibility complex.
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5. Targeted Therapeutics—The Second Wave
Targeting EpCAM has shown promise, but due to the environmental issues, as well as the
requirement for sufficient numbers of antibodies to surround each cancer cell in order to provoke
an immune response from CD16-positive cells, the next wave of antibodies sought to harness the
immune system by bringing the immune cells into close proximity with the tumour cells [35].
Catumaxomab is a trifunctional, bispecific antibody that binds to EpCAM, CD3-positive T cells,
and uses its Fc region to bind CD16-positive cells. Catumaxomab combines the characteristics of
classical monoclonal antibodies and bispecific molecules, and is known as a trifunctional, bispecific
antibody (Triomab®). The interaction of different immune effector cells at the tumour site results
in a complex immune reaction leading to the elimination of the tumour cells. This elimination was
studied in vitro and consisted of T cell mediated lysis, cytotoxicity by released cytokines, phagocytosis,
or ADCC [36,37]. Additionally, long-lasting anti-tumour immunity was demonstrated in a mouse
tumour model. When it entered clinical trials, tumour cells were eliminated, potentially through
an increase in cytokine release. Catumaxomab demonstrated clinical advantages and an acceptable
toxicity profile for treatment of malignant ascites [37], as well as excellent dose-response profiles [38],
and has been approved for clinical use following these successful trials [36].
Whereas, the Triomab® format of antibodies are composed of two different full-size IgG-like
half-antibodies [38], the bispecific T-cell engaging antibodies (BiTE®) are composed of two single
chain variable fragments, each with a unique antigen specificity [35]. While catumaxomab was
approved in the European Union in 2009 [39], the BiTE® antibody targeting EpCAM has been slower
to enter clinical trials. MT-110 has shown efficacy in several in vitro and in vivo studies, and has
completed phase I dose escalation studies (NCT00635596), though no further studies are currently
listed [35,36,40]. Very recent work has suggested that inhibiting immunosuppressive targets, such as
indoleamine 2, 3-dioxygenase (IDO), may enhance the effects of MT110 [41], which also suggests the
possibility of combining other similar immune inhibitors, such as programmed cell death protein-1
(PD-1) or cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), for improved treatment outcomes.
However, given the number of patients that have been recently diagnosed with autoimmune disorders
following treatment with nivolumab (PD-1) or ipilimumab (CTLA-4), extra care needs to be taken
when considering this [42].
For solid tumours, however, efficacy is very much dependent on the ability of the BiTE® antibodies
to penetrate into the tumour, as well as the presence of T-cells [35,36]. Given that these antibodies
are smaller than full-length antibodies, there is hope that they will demonstrate continued promise
for cancer patients. The one caveat to this is that they require functional T-cells, which may exhibit
signs of exhaustion, and enhanced trafficking of additional functional T-cells to the tumour may be
necessary to mitigate some of the non-responsiveness that is observed in patients [7,35,36].
6. Targeted Therapeutics—The Third Wave
In order to capitalise on the ability of antibodies to specifically target tumour cells, as well as
to produce an efficacious therapeutic, the next step in developing EpCAM as a target for enhanced
cytotoxicity has been to combine antibodies with cytotoxic drugs [1,29]. This would theoretically
combine the best of both worlds, with the specificity of monoclonal antibodies and the cytotoxicity
of small molecule drugs. Through the delivery of highly toxic drugs specifically into the cancer
cells, it would not only increase the therapeutic window of the drug, but would also reduce some of
the non-specific side effects observed in patients [1]. There have been a number of cytotoxic agents
considered for attachment to antibodies that target either microtubules or DNA, with success being
seen with compounds such as the maytansinoids, auristatins, calicheamicin, doxorubicin, paclitaxel
derivatives, and topoisomerase I inhibitors [1,29,43]. What should be noted, however, is that unlike the
first two examples that require external stimuli to kill the tumour cells, these antibody-drug conjugates
need to be internalised so that the drug can have an effect [1,29]. As well, the binding affinity and
number of antigen molecules on the cell surface may also affect the potency, as will the ratio of drug
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to antibody [1]. One study assessed the efficacy and concluded that a ratio of eight molecules of
doxorubicin to antibody was necessary for curative efficacy [44].
One interesting antibody-drug conjugate involves the attachment of a mushroom toxin to an
EpCAM antibody. Alpha-amanitin is the main component of the amatoxins and has been shown to
inhibit DNA transcription and lead to apoptosis. This drug was attached to the EpCAM antibody,
chiHEA125, through a glutarate linker with a ratio of between 4:1 and 8:1 drugs per antibody.
The conjugation of the drug to the antibody had no effect on binding affinity, and demonstrated
significant efficacy in an in vivo model of pancreatic carcinoma. As well as tumour volume decrease
and a lack of tumour recurrence, increased apoptosis and decreased tumour cell proliferation was also
observed [45]. A further drug that has been investigated for attachment to antibodies is the new class of
DNA alkylating agents, indolinobenzodiazepine pseudodimers (IGN), which possess a single reactive
imine group and are cytotoxic with high in vitro potency. Initial studies demonstrated troubling
toxicity, possibly due to the DNA cross-linking feature of the IGN dimer, so further investigation of
linking strategies were performed and the monoamine compound was found to alkylate DNA but
not cross-link. While dose-dependent antigen-specific antitumour activity was demonstrated with the
EpCAM-IGN, additional results are awaited [46].
Another innovation in this area is the use of photochemical internalisation (PCI), which is
a drug delivery technology for local and light controlled cytosolic release of therapeutics [47].
This technology can spare healthy tissue as the cytotoxic effect is limited to the illuminated area.
Lund and colleagues [47] linked saporin, a ribosome inactivating protein toxin, to an EpCAM antibody
via a biotin-strepavidin linker, and was shown to selectively reduce cellular viability, proliferative
capacity, and colony forming ability in vitro. Further studies are anticipated to demonstrate efficacy in
in vivo models.
While the size of antibodies has been recognised as a factor in ensuring sufficient drug
concentration within the tumour, smaller peptides have been investigated for targeted drug delivery.
Peptides were first proposed in 1992 as they are smaller than antibodies and are generally not
cleared by the reticuloendothelial system [48]. They are also fairly easily synthesised and modified,
and chemical modifications can prevent protein degradation [49]. However, while there are several
hundred peptide candidates in the clinic and preclinical development, there are only a few that
have been described for targeting EpCAM [49,50]. Designed Ankyrin Repeat Proteins (DARPins)
are a novel class of non-immunoglobulin binding proteins thart rely on the modularity of ankyrins.
Winkler and colleagues selected an EpCAM specific DARPin via ribosome display from a DARPin
library [50]. This group also evolved the selection process to develop EpCAM-specific DARPins
with picomolar affinity, and through the conjugation with a truncated form of the Pseudomonas
exotoxin A, demonstrated enhanced cytotoxicity in vitro [51]. Though it only demonstrated a short
half-life of 11 min, strong antitumour effects were observed in in vivo preclinical tumour models [52].
Macrocyclic peptides show higher affinity for their targets and possess higher resistance to degradation
by proteases, as well as reduced hydrogen bonding, allowing for increased membrane penetrating
potential [53]. A low nanomolar macrocyclic peptide has been generated to EpCAM using a random
non-standard peptide-integrated discovery (RaPID) system [54]. This macrocyclic peptide was later
attached to lipid nanoparticles and biodistribution and tumour targeting in vivo were investigated,
though with limited success, possibly due to the short circulation time [55]. It will be interesting to see
how these are further developed in the future.
7. Targeted Therapeutics—A New Hope?
One of the main issues with monoclonal antibodies is that there is insufficient penetration into the
tumour tissue due to the size of the antibodies. A recent paper by Xiang and colleagues tested the ability
of an EpCAM antibody to penetrate and be retained in vivo into a xenograft tumour [56]. In addition,
they compared this to a ‘chemical’ antibody, or aptamer as they are also known, to determine which
had the better biodistribution and pharmacokinetic profile. The chemical antibody has a higher
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accumulation in the tumour at both 3 and 24 h after intravenous administration, as well as a 4-fold
better penetration, and more homogenous distribution [56], suggesting that these agents may represent
a superior approach to targeted tumour therapeutics. These chemical antibodies, also known as
aptamers, demonstrate the same binding kinetics as antibodies, but have several properties that make
them more suited for the targeted delivery of therapeutics to solid tumours.
Aptamers are small, single stranded DNA or RNA oligonucleotides that bind to their targets in
a similar manner to antibodies [57–59]. The ability of aptamers to bind to their target molecules is
a result of their complex three-dimensional structures. Upon association with their target, aptamers
form complex molecular architectures in which their target becomes an integral part of their structure
via hydrogen bonding, van der Waals forces, and electrostatic interactions [58,60]. However, their other
properties, such as small size, a lack of immunogenicity, and a ‘tunable’ half-life, mean that these
aptamers can target solid tumours and act as agonists or antagonists, or deliver therapeutic cargoes
while overcoming some of the barriers that prevent antibodies having a higher efficacy (Figure 2).
Other notable advantages of aptamers over antibodies include the speed of generation (~2–8 weeks),
ease of synthesis, no or very limited batch-to-batch variation, and their physical and thermal
stability [58,60–63].
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Figure 2. Receptor mediated endocytosis of cytotoxic agents. Aptamer-drug conjugates bind to their
receptor, and are trafficked into the cell via receptor mediated endocytosis. Once in the lysosome,
the drug is released from the aptamer and is then excreted from the lysosome where it can then move to
the nucleus. If the drug is internalised non-specifically, drug-efflux pumps can pump the drugs outside
the cell quickly, thus limiting their concentration inside the cell. This is the same process whereby
antibody-drug conjugates can deliver a superior concentration of drug, as compared to non-specific
cytotoxic drugs.
While there are aptamers that work by blocking the function of their target, such as the
integrin DNA aptamer or VEGF aptamer [64,65] (and reviewed in [58,66]), the EpCAM aptamers
have been developed to deliver cytotoxic agents [67]. Doxorubicin is one of the most widely used
chemotherapeutic agents that is employed for a number of cancers, and has been previously linked
to antibodies for targeted therapeutics [44]. The way in which doxorubicin exerts its effects and
kills tumour cells is through intercalation into genomic DNA, thus disrupting replication and
transcription. Fairly early on in the development of aptamers as therapeutic agents, it was realised
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that because aptamers form tertiary conformations with short double-stranded nucleic acid regions,
they would require no or limited modifications for doxorubicin and an aptamer to form a physical
complex [58,59,68]. This was firstly demonstrated by Bagalkot and colleagues in 2006 using an aptamer
that targeted prostate specific membrane antigen, but was followed by a number of research
groups [69–72]. Xiang et al. [67]. This aptamer was modified from the original aptamer developed
to EpCAM [73] in that the double stranded stem was changed to G-C repeating DNA nucleotides
to enhance the intercalation of doxorubicin. In this study, it was demonstrated that 2–3 molecules
of doxorubicin intercalated into the stem of EpCAM aptamer, though if a higher efficacy is required,
the double-stranded stem of the aptamer can be extended to allow for further drug attachment [67].
Given that aptamers are strings of nucleotides, there are many linkers that can be used to attach
drugs to them with very limited modifications of the structure. The covalent coupling allows for the
drug to be attached separately to the aptamer, meaning that it is unlikely to have any major effects on
the specificity or sensitivity of the aptamer-drug conjugate. Additionally, the flexibility, pH sensitivity,
and even length, can tailor-make the conjugate, allowing for several biochemical and biophysical
parameters to be taken into account [68]. One drug conjugate attached via a cross-linker to an EpCAM
aptamer was neocarzinostatin [74]. Neocarzinostatin is an anti-tumour antibiotic protein chromophore
that has the ability to cleave double-stranded DNA [75]. In vitro studies demonstrated that this
aptamer-drug conjugate was able to arrest cell cycle and promote apoptosis and necrosis [75,76].
There is still a lot of scope for the development of these aptamers for the delivery of other
therapeutics. There have been a number of drugs conjugated to other aptamers which can easily
be attached to the EpCAM aptamers. For example, a recent study by Yoon et al. incorporated both
gemcitabine and 5-fluorouracil, or conjugated monomethyl auristatin E and derivative of maytansine 1
to an aptamer targeting pancreatic cancer [77]. These latter two agents are highly potent antimitotic
drugs, but also show high toxicity, limiting their use as cytotoxic agents, though they have shown
efficacy when conjugated to antibodies, as described previously. All four of these drugs were
simply attached to the aptamer, either via enzymatic or chemical conjugation. In vitro studies so
far have demonstrated a good efficacy of these agents [77], and it will be interesting to watch further
development of these agents in aptamer-drug conjugates and see if other aptamers can demonstrate
efficacy too.
Aptamers are not without their challenges for therapeutic delivery, which is why so far there
have only been a few commercialised aptamers [78], though there are now a number of aptamers
entering clinical trials. The first issue to overcome is the stability of aptamers in biological fluids,
with both their small size and nucleotide nature leading to renal excretion or nuclease degradation.
However, there are a number of modifications that can prevent degradation, such as modified DNA
and RNA bases, or 3’-capping with inverted thymidine bases [60]. The addition of drugs to the
aptamer increases the molecular weight of the complex and could impede renal clearance, though
it is very much dependent on the aptamer-drug conjugate having a molecular weight outside of the
30–50 kDa clearance range [79]. Finally, as aptamers are nucleotides, it is unsurprising that they have
a net negative charge which can make them impenetrable to biological barriers [80]. However, if the
aptamer is internalised following tight binding to its target, this electrostatic repulsive force effect
is limited and appears to be alleviated by the binding affinity of the aptamer [62]. Indeed, in one
study that directly compared the EpCAM antibody with the EpCAM aptamer in vivo, none of these
factors affected the concentration of aptamer in the tumour, and the aptamer behaved superiorly to the
antibody [56].
8. Conclusions
Antibodies were first described and tested as therapeutic agents almost 40 years ago and have
shown efficacy against a number of biomarkers for the targeted treatment of cancer. EpCAM was
one of the first biomarkers to be discovered, and there have been numerous clinical trials testing the
efficacy of antibody therapy. While there have been a number of missteps, with high affinity antibodies
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or the lack of stratification of patients based on EpCAM tumour expression, there have now been
some very successful trials in small cohorts of patients. However, in order to maximise EpCAM as
a therapeutic target, different modalities are also required that have different mechanisms of action
to monoclonal antibodies. Monoclonal antibodies are limited in their effects, either due to their lack
of solid tumour penetration, or their need for active engagement of CD16-positive immune cells.
Aptamers are smaller than antibodies, and thus can more effectively deliver drugs into the tumour.
Numerous studies have demonstrated that, despite theoretical implications of rapid renal clearance,
nuclease degradation, and electrostatic repulsion, aptamers are effective agents for the delivery of
cytotoxic agents. These agents can either be used as singular agents, or given their different mechanism
of action and suggested lack of drug-drug interaction, alongside antibodies to have a greater efficacy
against solid tumours. EpCAM is a viable target for therapeutic delivery, but different mechanisms of
action need to be considered in order for this almost ubiquitously expressed epithelial cancer biomarker
to be an effective target for future personalised therapy.
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